Mechanism of Action
PT-141 activates alpha-msh/" class="wiki-internal-link">melanocortin receptors in the brain, specifically targeting circuits involved in sexual behavior and arousal.
MC4R Activation in Hypothalamus
PT-141 agonizes melanocortin-4 receptors (MC4R) in the hypothalamus and limbic system, regions governing sexual motivation and behavior. MC4R activation increases dopamine release in the nucleus accumbens, a key mediator of sexual reward and drive. This central mechanism directly addresses desire rather than peripheral erectile/lubrication physiology.[1]MC3R and Reward Circuitry
MC3R activation by PT-141 modulates dopaminergic reward pathways, contributing to increased sexual motivation. MC3R is expressed in the arcuate nucleus and limbic areas and may regulate the appetitive (desire) component of sexual behavior independently of MC4R.[2]Distinction from PDE5 Inhibitors
PDE5 inhibitors (Viagra, Cialis) increase penile/clitoral blood flow by preventing cGMP degradation, they require sexual stimulation and primarily address erectile function. PT-141 activates desire at the neurological level, producing arousal independent of peripheral vascular effects. In erectile dysfunction research, PT-141 improved erections even in men who failed sildenafil.[3]Research Overview
Female HSDD (FDA Approved)
Phase III ClinicalFDA approval of Vyleesi (bremelanotide 1.75 mg SC) for HSDD in premenopausal women was based on Phase III RECONNECT trials. Studies showed significant improvements in desire domain scores and reductions in distress associated with low sexual desire. NNT of approximately 7 for meaningful desire improvement.[1]
Male Erectile Dysfunction
Phase II ClinicalPhase II trials in men with erectile dysfunction showed PT-141 produced erections sufficient for intercourse in 80% of subjects, including 67% of men who previously failed sildenafil. This suggests utility in PDE5-inhibitor non-responders where the underlying issue is central (desire/arousal) rather than purely vascular.[3]
PDE5-Inhibitor Non-Responders
Strong EvidencePT-141 central mechanism makes it complementary rather than redundant to PDE5 inhibitors. Case series and Phase II data show efficacy in psychological/central ED cases where penile blood flow is not the limiting factor. Combination use with PDE5 inhibitors has been explored.[3]
Calculate your PT-141 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| FDA protocol (women / HSDD) | 1.75 mg | As needed, max 1× per 24h | Subcutaneous (abdomen or thigh) |
| Research erectile protocol | 1–2 mg | As needed, max 1× per 24h | Subcutaneous |
| Titration / sensitivity start | 0.5–1 mg | As needed | Subcutaneous |
Administer 45-60 min before desired activity. Effects typically onset at 45 min and peak at 2-3 hours. Nausea (the most common side effect) onset mirrors peak plasma levels; taking 30 min before a light meal may reduce GI effects. Do not exceed one dose per 24 hours.
Research protocols only. FDA-approved dosing: 1.75 mg SC at least 45 min before sexual activity.
Interactions
Safety Profile
PT-141 is FDA approved with a defined safety profile from large Phase III trials.
Nausea: The most common adverse effect, occurring in ~40% of subjects in Phase III trials. Typically mild-moderate and resolves within 1-2 hours. Worse with higher doses; dose-limiting at 2+ mg.
Flushing: Facial/neck flushing from vasodilation occurs in ~20% of users. Usually transient.
Blood pressure: Transient increase in systolic blood pressure (mean +6 mmHg) observed in Phase III. Contraindicated in uncontrolled hypertension.
Hyperpigmentation: Unlike Melanotan II, approved PT-141 dosing rarely causes clinically significant pigmentation changes. Focal hyperpigmentation at injection sites reported rarely.
FDA approved: Vyleesi (bremelanotide 1.75 mg SC) is FDA approved for HSDD in premenopausal women. Off-label and research use exists for male dysfunction and at different doses.
References
- [1]Clayton AH, et al. "Bremelanotide for Female Sexual Dysfunctions in Premenopausal Women: A Randomized, Placebo-Controlled Dose-Finding Trial." Womens Health Issues. 2016;26(1):43-50. PMID:26209484
- [2]Pfaus JG, et al. "The melanocortins and sexual function." Peptides. 2004;25(9):1499-1507. PMID:15501120
- [3]Diamond LE, et al. "Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141." Int J Impot Res. 2004;16(1):51-59. PMID:14963488